NASDAQ:HELP

Cybin Q1 2027 Earnings Results & Report

Cybin logo
$6.11 -0.67 (-9.88%)
Closing price 04:00 PM Eastern
Extended Trading
$6.16 +0.05 (+0.90%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cybin missed analyst earnings expectations in its Q1 2027 results, released August 14, 2026. The company reported EPS of -$0.91 versus the -$0.80 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Cybin EPS Results

Actual EPS
-$0.91
Consensus EPS
-$0.80
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Cybin Q1 2027 Earnings FAQ

Cybin (NASDAQ:HELP) reported earnings of -$0.91 per share for Q1 2027, missing the consensus estimate of -$0.80. The report was announced on Friday, August 14, 2026.

Cybin Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP), which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders.

The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder. These compounds remain investigational and are not approved medicines.

Founded in 2019, the company has conducted clinical development activities in multiple countries. Doug Drysdale has served as its chief executive officer.

View Cybin Profile